INSM
Price
$112.93
Change
+$3.31 (+3.02%)
Updated
Aug 11, 04:59 PM (EDT)
Capitalization
23.16B
73 days until earnings call
MDWD
Price
$18.72
Change
+$0.09 (+0.48%)
Updated
Aug 11 closing price
Capitalization
203.29M
2 days until earnings call
Interact to see
Advertisement

INSM vs MDWD

Header iconINSM vs MDWD Comparison
Open Charts INSM vs MDWDBanner chart's image
Insmed
Price$112.93
Change+$3.31 (+3.02%)
Volume$79.59K
Capitalization23.16B
MediWound
Price$18.72
Change+$0.09 (+0.48%)
Volume$40.84K
Capitalization203.29M
INSM vs MDWD Comparison Chart in %
Loading...
INSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDWD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INSM vs. MDWD commentary
Aug 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INSM is a Hold and MDWD is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 12, 2025
Stock price -- (INSM: $109.62 vs. MDWD: $18.72)
Brand notoriety: INSM and MDWD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INSM: 82% vs. MDWD: 73%
Market capitalization -- INSM: $23.87B vs. MDWD: $203.29M
INSM [@Biotechnology] is valued at $23.87B. MDWD’s [@Biotechnology] market capitalization is $203.29M. The market cap for tickers in the [@Biotechnology] industry ranges from $96.01B to $0. The average market capitalization across the [@Biotechnology] industry is $1.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INSM’s FA Score shows that 1 FA rating(s) are green whileMDWD’s FA Score has 1 green FA rating(s).

  • INSM’s FA Score: 1 green, 4 red.
  • MDWD’s FA Score: 1 green, 4 red.
According to our system of comparison, INSM is a better buy in the long-term than MDWD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INSM’s TA Score shows that 4 TA indicator(s) are bullish while MDWD’s TA Score has 4 bullish TA indicator(s).

  • INSM’s TA Score: 4 bullish, 4 bearish.
  • MDWD’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, INSM is a better buy in the short-term than MDWD.

Price Growth

INSM (@Biotechnology) experienced а +2.18% price change this week, while MDWD (@Biotechnology) price change was +1.91% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +22.22%. For the same industry, the average monthly price growth was +31.78%, and the average quarterly price growth was +19.63%.

Reported Earning Dates

INSM is expected to report earnings on Oct 23, 2025.

MDWD is expected to report earnings on Aug 14, 2025.

Industries' Descriptions

@Biotechnology (+22.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INSM($23.2B) has a higher market cap than MDWD($203M). INSM YTD gains are higher at: 58.778 vs. MDWD (5.169). MDWD has higher annual earnings (EBITDA): -29.43M vs. INSM (-917.87M). INSM has more cash in the bank: 1.2B vs. MDWD (38.3M). MDWD has less debt than INSM: MDWD (6.42M) vs INSM (1.14B). INSM has higher revenues than MDWD: INSM (381M) vs MDWD (19.2M).
INSMMDWDINSM / MDWD
Capitalization23.2B203M11,429%
EBITDA-917.87M-29.43M3,119%
Gain YTD58.7785.1691,137%
P/E RatioN/AN/A-
Revenue381M19.2M1,984%
Total Cash1.2B38.3M3,131%
Total Debt1.14B6.42M17,793%
FUNDAMENTALS RATINGS
INSM vs MDWD: Fundamental Ratings
INSM
MDWD
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
65
Fair valued
PROFIT vs RISK RATING
1..100
10100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
3858
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDWD's Valuation (65) in the Pharmaceuticals Other industry is in the same range as INSM (76) in the Biotechnology industry. This means that MDWD’s stock grew similarly to INSM’s over the last 12 months.

INSM's Profit vs Risk Rating (10) in the Biotechnology industry is significantly better than the same rating for MDWD (100) in the Pharmaceuticals Other industry. This means that INSM’s stock grew significantly faster than MDWD’s over the last 12 months.

MDWD's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as INSM (100) in the Biotechnology industry. This means that MDWD’s stock grew similarly to INSM’s over the last 12 months.

INSM's Price Growth Rating (38) in the Biotechnology industry is in the same range as MDWD (58) in the Pharmaceuticals Other industry. This means that INSM’s stock grew similarly to MDWD’s over the last 12 months.

MDWD's P/E Growth Rating (4) in the Pharmaceuticals Other industry is significantly better than the same rating for INSM (100) in the Biotechnology industry. This means that MDWD’s stock grew significantly faster than INSM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INSMMDWD
RSI
ODDS (%)
Bearish Trend 4 days ago
88%
Bullish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
66%
Bullish Trend 4 days ago
90%
Momentum
ODDS (%)
Bullish Trend 4 days ago
68%
Bearish Trend 4 days ago
82%
MACD
ODDS (%)
Bullish Trend 4 days ago
82%
Bearish Trend 4 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
72%
Bullish Trend 4 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
73%
Bearish Trend 4 days ago
78%
Advances
ODDS (%)
Bullish Trend 11 days ago
69%
Bullish Trend 5 days ago
76%
Declines
ODDS (%)
Bearish Trend 5 days ago
75%
Bearish Trend 11 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
72%
Bullish Trend 4 days ago
81%
Aroon
ODDS (%)
Bullish Trend 4 days ago
73%
Bearish Trend 4 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
INSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDWD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
HCMT34.640.63
+1.85%
Direxion HCM Tactical EnhU.S.EqStratETF
BNOV42.170.24
+0.57%
Innovator US Equity Buffer ETF Nov
BUFM37.250.14
+0.38%
AB Moderate Buffer ETF
IRTR29.870.01
+0.03%
iShares LifePath Retirement ETF
IVOO105.84-0.01
-0.01%
Vanguard S&P Mid-Cap 400 ETF

INSM and

Correlation & Price change

A.I.dvisor indicates that over the last year, INSM has been closely correlated with THAR. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if INSM jumps, then THAR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INSM
1D Price
Change %
INSM100%
+0.29%
THAR - INSM
76%
Closely correlated
-2.06%
NWPHF - INSM
49%
Loosely correlated
N/A
CARM - INSM
44%
Loosely correlated
-1.82%
ROIV - INSM
42%
Loosely correlated
-0.52%
CRNX - INSM
41%
Loosely correlated
-3.69%
More